Insights from 2023 ASH Annual Meeting
Playback speed
10 seconds
ASH 2023 Insights: "MRD-Guided Acalabrutinib, Venetoclax and Obinutuzumab in R/R CLL From the CLL2-BAAG Trial"
By
Insights from 2023 ASH Annual Meeting
FEATURING
Moritz Fürstenau
By
Insights from 2023 ASH Annual Meeting
FEATURING
Moritz Fürstenau
61 views
December 29, 2023
Comments 0
Login to view comments.
Click here to Login
Leukemia